The author lists five key areas to consider when selecting a CDMO to develop highly potent formulations.
Robert Harris
Advertisement
Articles by Robert Harris
The determination of topical bioequivalence requires a multi-faceted approach, tailored specifically to the generic-drug formulation.
Advertisement
Latest Updated Articles
Demonstrating Therapeutic Equivalence for Generic Topical ProductsPublished: November 2nd 2015 | Updated:
Outsourcing Formulation Development for High-Potency CompoundsPublished: March 1st 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Sustainability and Stability in Excipients
2
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
3
Turning Real-World Data into Actionable Drug Development Insights With AI
4
The Key Trends Driving Supply Chain Localization and Data Scrutiny in Biopharma
5
